Cell Expansion Market Worth $14.8 Billion by 2019

DALLAS, October 29, 2014 /PRNewswire/ — According to the new market research report The " Cell Expansion Market by Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), …

View original post here:
Cell Expansion Market Worth $14.8 Billion by 2019

Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr Mobile More Celebrity Movies Music TV Health Style Beauty Food Parenting DIY Tech Shopping Travel Autos Homes Sign In Mail Help Account Info Help Suggestions

Read more:
Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment

Stem Cell Therapy BACKSTAGE – Video



Stem Cell Therapy BACKSTAGE

By:

Read this article:
Stem Cell Therapy BACKSTAGE – Video

Report: Stem Cell Technologies Market Growing

NEW YORK, Oct. 31, 2014 /PRNewswire/ — Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching …

See more here:
Report: Stem Cell Technologies Market Growing

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Published on October 31, 2014 at 8:10 AM

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information’s report, Stem Cell Therapeutics Markets.This includes revenues from proprietary stem cell therapeutics that have gained or are expected to gain approval from respected regulatory authorities.

“As drug developers tackle ever more complicated conditions, stem cell therapies hold the promise of addressing a large number of diseases,” said Melissa Elder, the author of the report.”It must be noted, however, that in most cases this research is in a very early stage and is hindered by an incomplete understanding of each condition and the role stem cells play in treatment.”

The healthcare market researcher’s report notes that there are more than 4,000 research projects underway for stem cell therapies throughout the world.About a dozen companies are currently evaluating stem cell therapies in late stage clinical trials, among them Aastrom Biosciences, Advanced Cell Technology, Athersys, Cytori Therapeutics, GlaxoSmithKline, and Neuralstem, Inc.

Stem cells have advanced beyond the research lab to become effective tools in the treatment of some blood diseases, circulatory diseases, digestive disorders, musculoskeletal diseases, neoplasms and skin and subcutaneous tissue disorders.The most commonly used and/or approved stem cell therapies are largely confined to selected oncological conditions such as leukemia, multiple myeloma and non-Hodgkin’s lymphoma, although certain non-cancerous diseases like aplastic anemia, immunodeficiency and lupus are increasingly addressed with stem cells.Additionally, the use of stem cells in wound and dental applications is finding greater acceptance.

6149da1c-9b91-4520-8b77-4d6782ef6a60|0|.0

Posted in: Device / Technology News | Medical Science News

Tags: Anemia, Aplastic Anemia, Blood, Cell, Diagnostics, Healthcare, Hodgkin’s Lymphoma, Immunodeficiency, Leukemia, Lupus, Lymphoma, Multiple Myeloma, Musculoskeletal, Myeloma, Non-Hodgkin’s Lymphoma, Stem Cell

Read the original post:
Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Vitro Biopharma Launches new Cell Lines to Bolster Revenue Growth

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr Mobile More Celebrity Movies Music TV Health Style Beauty Food Parenting DIY Tech Shopping Travel Autos Homes Sign In Mail Help Account Info Help Suggestions

The rest is here:
Vitro Biopharma Launches new Cell Lines to Bolster Revenue Growth

Changes in cell metabolism slow growth of colorectal cancer

Cancer is an unwanted experiment in progress. As the disease advances, tumor cells accumulate mutations, eventually arriving at ones that give them the insidious power to grow uncontrollably and spread. Distinguishing drivers of cancer from benign mutations open opportunities for developing targeted cancer therapies.

A University of Utah-led study reports that cancers select against a protein complex called the mitochondrial pyruvate carrier (MPC), and re-introduction of MPC in colon cancer cells impairs several properties of cancer, including growth. The research, which appears online on Oct. 30 in Molecular Cell, implicates changes in a key step in metabolism – the way cellular fuel is utilized – as an important driver of colon cancer that is also likely to be important in many other cancer settings.

Cancers appear to do whatever they can to get rid of MPC, a protein involved in carbohydrate metabolism, shows the study led by Jared Rutter, Ph.D., professor of biochemistry and Dee Glen and Ida W. Smith Endowed Chair for Cancer Research at the University of Utah. At least 18 types of cancers – colon, brain, breast, and liver among them – have significantly less MPC than normal adult cells. Some cancers simply delete a region of the genome that contains one of the MPC genes, others find different ways to dampen MPC expression. In fact, a survey of patient biopsies shows that the less MPC there is, the more aggressive the cancer becomes.

“Loss of MPC seems to be a biomarker for cancer aggressiveness and patient survival,” said Rutter, also co-director of the Diabetes and Metabolism Center at the University of Utah, and co-leader of the Nuclear Control of Cell Growth and Differentiation Program at the Huntsman Cancer Institute. “That was our first clue that MPC might be important.”

Even more striking, when Rutter’s group reintroduced MPC into colon cancer cell lines, properties that define them as cancerous, reverted. The cells divide less frequently under certain conditions and decrease expression of stem cell markers, an early step frequently defining the potential to form tumors and spread. Further, the engineered cells are dramatically impaired in their ability to form tumors after injection into mice. Tumors containing cells with MPC were as small as one-fourth the size of tumors made from cells without the protein complex.

“We think these results show that elimination of MPC is an early and important step in development of cancer,” said John Schell, who is co-first author with Kristofor Olson, both M.D.-Ph.D. students at the University of Utah. “Finding the stem cell connection was probably the most exciting part for us, and is something we’ll pursue further to understand how loss of MPC changes cell behavior.”

The role of MPC in the normal cell, and what loss of MPC does to a cancer cell, addresses an observation first made nearly one century ago. Nobel Prize-wining biochemist Otto Warburg noted that cancer cells change their metabolism to support uncontrolled growth and proliferation. Scientists later found the way in which the metabolite pyruvate is processed is key to these metabolic changes. In normal adult cells, pyruvate enters the mitochondria, the cell’s powerhouse, and fuels energy production. In cancer, pyruvate is diverted from the mitochondria to an alternative metabolic pathway that makes cell-building material.

Scientists had long suspected the so-called Warburg effect seen in cancer was contingent upon controlling entry of pyruvate into the mitochondria. But there was no way to directly test the idea until two years ago, when Rutter’s group and others identified MPC as pyruvate’s doorway to the mitochondria. The current report in Molecular Cell shows that cancer cells shut that door by repressing MPC, and that experimentally re-opening the door by re-introducing MPC not only inhibits cancer growth, but also redirects pyruvate to the metabolic pathway used in normal cells. In other words, MPC counteracts the Warburg effect.

“This makes sense because MPC is a pinch point in metabolism,” said Rutter. “Our work, taken together with that from many other laboratories, shows that most cancer cells are completely reliant on this unusual metabolism known as the Warburg effect.”

Understanding the Warburg effect has been an area of intense interest in recent years because of the potential to translate those discoveries into new cancer therapeutics. “We think this information can be used to design therapies that are specifically toxic to cancer cells,” said Rutter.

Read the original:
Changes in cell metabolism slow growth of colorectal cancer

Rewiring Metabolism Slows Colorectal Cancer Growth

Contact Information

Available for logged-in reporters only

-Many types of cancers (including brain, breast, and colon) have significantly less of a protein complex, called the mitochondrial pyruvate carrier (MPC), within them as compared to normal tissue.

-The amount of MPC within a patients tumor correlates with patient survival: the less MPC, the more aggressive the cancer.

-Re-introduction of MPC into cancer cells inhibits tumor growth, when cells are grown under conditions commonly used for assessing tumor initiation and metastasis, including after injection into mice.

-Known as the Warburg effect, changes in metabolism have long been known to be important for supporting uncontrolled growth in cancer. MPC, which operates at a critical branch point in carbohydrate metabolism, counteracts the Warburg effect.

-The finding opens new opportunities for developing cancer therapeutics.

Rewiring Metabolism Slows Colorectal Cancer Growth

Newswise (SALT LAKE CITY) – Cancer is an unwanted experiment in progress. As the disease advances, tumor cells accumulate mutations, eventually arriving at ones that give them the insidious power to grow uncontrollably and spread. Distinguishing drivers of cancer from benign mutations open opportunities for developing targeted cancer therapies.

A University of Utah-led study reports that cancers select against a protein complex called the mitochondrial pyruvate carrier (MPC), and re-introduction of MPC in colon cancer cells impairs several properties of cancer, including growth. The research, which appears online on Oct. 30 in Molecular Cell, implicates changes in a key step in metabolism the way cellular fuel is utilized as an important driver of colon cancer that is also likely to be important in many other cancer settings.

Here is the original post:
Rewiring Metabolism Slows Colorectal Cancer Growth

ACL Injuries in Dogs and Stem Cell Regenerative Therapy

The suggested solution, a TPLO to repair her lame leg, with a prognosis for a second surgery on the right knee in six months time, was quite a blow. This would add up to two invasive surgeries and a total of one year of recovery.

On a quest to find an alternative, we looked into all other options. (See Talk To Me About ACL Injuries). During our research we came across information about stem cell regenerative therapy for dogs.

We found that stem cell regenerative therapy has been used to treat tendon, ligament, and joint injuries in horses, and that it is available for dogs also. We decided to pursue this.

Unfortunately, a couple days before our stem cell treatment consultation, Jasmine’s ACL tore completely, and a non-surgical solution was no longer an option.

Our final decision was an extracapsular repair for the torn ACL, combined with the stem cell therapy to assist the post-op recovery, and to see if it can save the right knee.

The healing effect on the operated leg turned out remarkable. The right leg was also looking good, and three months after surgery Jasmine had a bounce back in her step.

And then the ligament in the right knee went. It was a big disappointment. Back to surgery and back to rehab.

Fortunately though, her left leg was already stable enough to provide full support. That’s why we decided to combine the second surgery with the stem cell treatment again. Another three months later, Jasmine was bouncing along and enjoying her life yet again.

The stem cell regenerative therapy is showing great results in treatment of arthritis, and many other conditions. However, it was not able to save Jasmine’s ligament.

I believe this happened for several reasons.

See the original post here:
ACL Injuries in Dogs and Stem Cell Regenerative Therapy